Clinical and ultrasound characteristics in patients with sars-cov-2 pneumonia, associated with hospitalization prognosis. e-covid project.

Clinical and ultrasound characteristics in patients with sars-cov-2 pneumonia, associated with hospitalization prognosis. e-covid project.

Publication date: Dec 31, 2024

During the COVID-19 pandemia, the imaging test of choice to diagnose COVID-19 pneumonia as chest computed tomography (CT). However, access was limited in the hospital setting and patients treated in Primary Care (PC) could only access the chest x-ray as an imaging test. Several scientific articles that demonstrated the sensitivity of lung ultrasound, being superior to chest x-ray [Cleverley J et al. , BMJ 370, 202013] and comparable to CT scan [Tung-Chen Y et al. , Ultrasound Med Biol 46:2918-2926, 2020], promoted the incorporation of this technique in the assessment of COVID-19 patients in PC. [PcE9rez J et al. , Arch. Bronconeumol 56:27-30, 2020; Gargani L et al. , Eur Heart J Cardiovasc Imaging 21:941-8, 2020, Soldati G et al. , J Ultrasound Med 39:1459, 2020] A prior study in our territory (Lleida, Spain) was designed to predict complications (hospital admission) of COVID-19 pneumonia in PC patients, being different patterns of Lung ultrasounds (LUS) risk factors for hospital admission. [MartcEDnez Redondo J et al. , Int J Environ Res Public Health 18:3481, 2021] The rationale for conducting this study lies in the urgent need to understand the determinants of severity and prognosis in COVID-19 patients with interstitial pneumonia, according to its lung ultrasound patterns. This research is crucial to provide a deeper understanding of how these pre-existing ultrasound patterns related to disease progression influence the medical treatment. The objective of the study is to generate predictive models of lung ultrasound patterns for the prediction of lung areas characteristics associated with hospitalizations and admissions to the Intensive Care Unit (ICU) associated with COVID-19 disease, using ultrasound, sociodemographic and medical data obtained through the computerized medical history. A single relevant variable has been found for the prediction of hospitalization (number of total regions with potentially pathological presence of B lines) and one for the prediction of ICU admission (number of regions of the right lung with potentially pathological presence of B lines). In both cases it has been determined that the optimal point for classification was 2 or more lung affected areas. Those areas under the curve have been obtained with good predictive capacity and consistency in both cohorts. The results of this study will contribute to the determination of the ultrasound prognostic value based on the number of lung areas affected, the presence of pulmonary condensation or the irregularity of pleural effusion patterns in COVID-19 patients, being able to be extended to other lung viral infections with similar patterns.

Open Access PDF

Concepts Keywords
202013and Aged
Conducting COVID-19
Pc Female
Pneumonia Hospitalization
Ultrasounds Hospitalization
Humans
Lung
Male
Middle Aged
Primary health care
Prognosis
Prognosis
Risk Factors
SARS-CoV-2
SARS-CoV-2
Spain
Tomography, X-Ray Computed
Ultrasonography
Ultrasound

Semantics

Type Source Name
disease MESH pneumonia
disease MESH COVID-19
disease MESH complications
disease MESH interstitial pneumonia
disease MESH disease progression
disease IDO history
disease MESH pleural effusion
disease MESH viral infections
pathway REACTOME Reproduction
drug DRUGBANK Esomeprazole
disease MESH emergency
disease MESH respiratory failure
drug DRUGBANK Trestolone
disease MESH death
disease MESH critically ill
disease MESH infection
disease MESH Respiratory Infections
drug DRUGBANK Oxygen
drug DRUGBANK Ethionamide
drug DRUGBANK Penciclovir
drug DRUGBANK Ilex paraguariensis leaf
drug DRUGBANK Saquinavir
drug DRUGBANK Tretamine
disease MESH lung disease
disease MESH inflammation
disease MESH edema
disease MESH respiratory diseases
disease MESH lung injury
drug DRUGBANK Coenzyme M
disease IDO blood
disease MESH sepsis
disease MESH pulmonary edema
disease IDO process
disease MESH Acute Respiratory Distress Syndrome
drug DRUGBANK Filgrastim
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH Comas
disease MESH Chronic Obstructive Lung Disease
drug DRUGBANK Gold

Original Article

(Visited 1 times, 1 visits today)